193 related articles for article (PubMed ID: 38335406)
41. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Zhou JB; Tang X; Han M; Yang J; Simó R
Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
[TBL] [Abstract][Full Text] [Related]
42. Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients-the role of antidiabetic and antihypertensive medications.
Kitamura K; Hayashi K; Ito S; Hoshina Y; Sakai M; Yoshino K; Endo K; Fujitani S; Suzuki T
Hypertens Res; 2021 May; 44(5):508-517. PubMed ID: 33311577
[TBL] [Abstract][Full Text] [Related]
43. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
Hong D; Si L; Jiang M; Shao H; Ming WK; Zhao Y; Li Y; Shi L
Pharmacoeconomics; 2019 Jun; 37(6):777-818. PubMed ID: 30854589
[TBL] [Abstract][Full Text] [Related]
44. Hypertension, antihypertensive drugs, and age at onset of Huntington's disease.
Zhu Y; Li M; Bai J; Wang H; Huang X
Orphanet J Rare Dis; 2023 May; 18(1):125. PubMed ID: 37226269
[TBL] [Abstract][Full Text] [Related]
45. [Retrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy].
Demidova TY; Lobanova KG; Perekhodov SN; Antsiferov MB; Oynotkinova OS
Ter Arkh; 2021 Oct; 93(10):1193-1202. PubMed ID: 36286821
[TBL] [Abstract][Full Text] [Related]
46. Prescribing patterns and therapeutic implications for diabetic hypertension in Bahrain.
Al Khaja KA; Sequeira RP; Mathur VS
Ann Pharmacother; 2001 Nov; 35(11):1350-9. PubMed ID: 11724081
[TBL] [Abstract][Full Text] [Related]
47. Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study.
Yan H; Valdes AM; Vijay A; Wang S; Liang L; Yang S; Wang H; Tan X; Du J; Jin S; Huang K; Jiang F; Zhang S; Zheng N; Hu Y; Cai T; Aithal GP
Clin Pharmacol Ther; 2020 Dec; 108(6):1185-1194. PubMed ID: 32910830
[TBL] [Abstract][Full Text] [Related]
48. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
[TBL] [Abstract][Full Text] [Related]
49. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
50. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
COVID-19 RISk and Treatments (CORIST) Collaboration
Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
[TBL] [Abstract][Full Text] [Related]
51. Mendelian randomization reveals no causal relationship between COVID-19 susceptibility, hospitalization, or severity and epilepsy.
He Z; Li Y; Liu S; Li J
Epilepsia Open; 2023 Dec; 8(4):1452-1459. PubMed ID: 37602490
[TBL] [Abstract][Full Text] [Related]
52. No causal association between atopic dermatitis and COVID-19 outcomes: A Mendelian randomization study.
Jin C; Li Y
Skin Res Technol; 2024 Feb; 30(2):e13619. PubMed ID: 38369908
[TBL] [Abstract][Full Text] [Related]
53. Antihypertensive drug use and psoriasis: A systematic review, meta- and network meta-analysis.
Song G; Yoon HY; Yee J; Kim MG; Gwak HS
Br J Clin Pharmacol; 2022 Mar; 88(3):933-941. PubMed ID: 34611920
[TBL] [Abstract][Full Text] [Related]
54. Associations Between Antihypertensive Medications and Severe Hyponatremia: A Swedish Population-Based Case-Control Study.
Falhammar H; Skov J; Calissendorff J; Nathanson D; Lindh JD; Mannheimer B
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3696-705. PubMed ID: 32285124
[TBL] [Abstract][Full Text] [Related]
55. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Ren L; Yu S; Xu W; Overton JL; Chiamvimonvat N; Thai PN
J Cardiol; 2021 May; 77(5):482-491. PubMed ID: 33168337
[TBL] [Abstract][Full Text] [Related]
56. The causal role of gut microbiota in susceptibility and severity of COVID-19: A bidirectional Mendelian randomization study.
Chen H; Ye B; Su W; Song Y; Sun PL; Zhou X; Zhang G
J Med Virol; 2023 Jul; 95(7):e28880. PubMed ID: 37409643
[TBL] [Abstract][Full Text] [Related]
57. Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis.
Kuate Defo A; Bakula V; Pisaturo A; Labos C; Wing SS; Daskalopoulou SS
Diabetes Obes Metab; 2024 Feb; 26(2):441-462. PubMed ID: 37869901
[TBL] [Abstract][Full Text] [Related]
58. The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.
Chen Y; Lv X; Lin S; Arshad M; Dai M
Front Endocrinol (Lausanne); 2022; 13():895458. PubMed ID: 35692410
[TBL] [Abstract][Full Text] [Related]
59. The impact of immunoglobulin G N-glycosylation level on COVID-19 outcome: evidence from a Mendelian randomization study.
Long F; Xiao C; Cui H; Wang W; Jiang Z; Tang M; Zhang W; Liu Y; Xiang R; Zhang L; Zhao X; Yang C; Yan P; Wu X; Wang Y; Zhou Y; Lu R; Chen Y; Li J; Jiang X; Fan C; Zhang B
Front Immunol; 2023; 14():1217444. PubMed ID: 37662938
[TBL] [Abstract][Full Text] [Related]
60. Periodontal disease increases the host susceptibility to COVID-19 and its severity: a Mendelian randomization study.
Wang Y; Deng H; Pan Y; Jin L; Hu R; Lu Y; Deng W; Sun W; Chen C; Shen X; Huang XF
J Transl Med; 2021 Dec; 19(1):528. PubMed ID: 34952598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
